Brentuximab vedotin plus nivolumab as bridging therapy to CAR T-cells in relapsed/refractory primary mediastinal B-cell lymphoma.

IF 7.9 1区医学 Q1 HEMATOLOGY

Haematologica Pub Date : 2025-09-18 DOI:10.3324/haematol.2025.287672

Armando Santoro,Ciro Maria Improta,Barbara Sarina,Daniele Mannina,Chiara De Philippis,Daniela Taurino,Jacopo Mariotti,Monica Balzarotti,Stefania Bramanti

引用次数: 0

Abstract

Not available.

查看原文本刊更多论文

Brentuximab vedotin联合nivolumab作为CAR - t细胞桥接疗法治疗复发/难治性原发性纵隔b细胞淋巴瘤。

不可用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Haematologica 医学-血液学

CiteScore

14.10

自引率

2.00%

发文量

349

审稿时长

3-6 weeks

期刊介绍： Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.